A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT ID: NCT06997029
Last Updated: 2026-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
234 participants
INTERVENTIONAL
2025-08-01
2028-12-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
NCT05298592
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06697197
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
NCT05625412
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
NCT00420186
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1A Monotherapy Dose Escalation
BMS-986500
Specified dose of specified days
Part 1B Combination Dose Escalation
BMS-986500
Specified dose of specified days
Palbociclib
Specified dose on specified days
Fulvestrant
Specified dose on specified days
Part 1C Monotherapy Pharmacodynamic (PD) Sub-study
BMS-986500
Specified dose of specified days
Part 2A Monotherapy Dose Expansion
BMS-986500
Specified dose of specified days
Part 2B Combination Dose Expansion
BMS-986500
Specified dose of specified days
Palbociclib
Specified dose on specified days
Fulvestrant
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986500
Specified dose of specified days
Palbociclib
Specified dose on specified days
Fulvestrant
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy.
* Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
* Participants must have a stable Eastern Cooperative Oncology Group Performance Status of 0 or 1.
* For Part 2A only, participants must have CCNE1-amplified ovarian cancer
Exclusion Criteria
* Participants must not have impaired cardiac function or clinically significant cardiac disease.
* Participants must not have bleeding disorder or any history of clinically significant bleeding within the prior 3 months.
* Participants must not have Grade ≥ 2 peripheral neuropathy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Providence St. Jude Medical Center
Fullerton, California, United States
Marin Cancer Care
Greenbrae, California, United States
Moores Cancer Center
La Jolla, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Local Institution - 0008
Aurora, Colorado, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Washington University School of Medicine
St Louis, Missouri, United States
Local Institution - 0002
Lebanon, New Hampshire, United States
Local Institution - 0014
Buffalo, New York, United States
Northwell Health-Cancer Institute
New Hyde Park, New York, United States
Local Institution - 0011
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
START Dallas Fort Worth
Fort Worth, Texas, United States
NEXT Oncology
San Antonio, Texas, United States
Local Institution - 0024
Odense, Region Syddanmark, Denmark
Local Institution - 0025
Copenhagen, , Denmark
Local Institution - 0021
Kashiwa, Chiba, Japan
Kansai Medical University Hospital
Hirakata, Osaka, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, www.BMSStudyConnect.com
Role: CONTACT
First line of the email MUST contain NCT # and Site #.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mehmet Akce, Site 0001
Role: primary
Yung Lyou, Site 0003
Role: primary
Cyrus Mazidi, Site 0013
Role: primary
Peter Vu, Site 0009
Role: primary
Monica Mita, Site 0010
Role: primary
Site 0008
Role: primary
Joyce Liu, Site 0006
Role: primary
Faisal Fa'ak, Site 0004
Role: primary
Site 0002
Role: primary
Site 0014
Role: primary
Geraldine O'Sullivan Coyne, Site 0016
Role: primary
Site 0011
Role: primary
Ezra Rosen, Site 0012
Role: primary
Henry Xiong, Site 0018
Role: primary
David Sommerhalder, Site 0007
Role: primary
Site 0024
Role: primary
Site 0025
Role: primary
Site 0021
Role: primary
Toshio Shimizu, Site 0020
Role: primary
Takafumi Koyama, Site 0022
Role: primary
Shigehisa Kitano, Site 0023
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-524334-26-00
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1330-3304
Identifier Type: OTHER
Identifier Source: secondary_id
CA243-0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.